Canadian Perspective on Overall survival (OS) in KATE2.
Watch Now
KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.
Watch Now
Message from our Editor-in-Chief
Watch Now
Message from our Scientific Editor
Watch Now
Identifying Research Priorities in Prediction of Response in Patients with Early Breast Cancer
Watch Now